SeQuent Scientific announces Q4FY15 results

SeQuent’s net loss stood at Rs 12 crore as compared to a loss of Rs 110 crore in FY14. According to the company's statement, its R&D pipeline currently has around 30 products under development.

manishgupta-200

Mr Manish Gupta, MD, SeQuent Scientific

SeQuent Scientific, an integrated pharmaceutical company with business across animal health, niche human APIs & analytical services announced its financial results for the fourth quarter ended March 31, 2015 (Q4FY15) and full year ended March 31, 2015 (FY15).

The company's operating revenue was Rs 133 crore as compared to Rs 107 crore in Q4FY14.

Adjusted EBITDA stood at Rs 20 crore as compared to a loss of Rs 4 crore during the corresponding period of previous year.

Net loss stood at Rs 19 crore for Q4FY15 as compared to a loss of Rs 80 crore in the corresponding period of the previous year.

The operating revenue stood at Rs 465 crore as compared to Rs 455 crore in FY14. Net loss stood at Rs 12 crore as compared to a loss of Rs 110 crore in FY14.

 

Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X